Founded by a team of PhD doctors and scientists from Johns Hopkins University, Harvard University, University of California, Berkeley, and Stanford University, Pendulum is redefining the future of microbiome science through next-generation probiotics developed using cutting-edge research and proprietary anaerobic manufacturing technology in its own strict oxygen-free facility in the USA. Known globally for pioneering live anaerobic bacterial strains, Pendulum was the first company to successfully stabilize and commercialize Akkermansia muciniphila - one of the most researched beneficial gut bacteria linked to metabolic and digestive health. Pendulum’s targeted microbiome formulations are designed to support blood sugar balance, type 2 diabetes management, gut microbiome diversity, digestive health, metabolic disorders, cravings, glucose control, insulin sensitivity, inflammation, gut barrier integrity, and overall gut dysfunction using clinically studied probiotic strains backed by advanced microbiome science.